Cannabis Science Pioneer Tikun Olam Expands Partnership with MariMed to Bring Branded Cannabis Products to More U.S. MMJ States
Deal Combines Tikun Products & Unparalleled Research with MariMed's Cultivation & Distribution Networks
NEWTON, Mass. and NEW YORK, Sept. 19, 2017 /PRNewswire/ -- Tikun Olam, the world pioneer in cannabis research, and MariMed Inc. (OTCQB:MRMD), a preeminent management company in the U.S. medical cannabis industry, announced an expansion of their licensing agreement for Tikun Olam products to be grown, manufactured and sold through MariMed's network of managed and affiliated licensed facilities throughout the United States.
This new agreement brings Tikun Olam's premium cannabis products, years of proprietary, peer-reviewed scientific research and unprecedented clinical data collection to four additional MMJ-legal U.S. states, its most expansive agreement to date. Tikun Olam and MariMed's relationship began in 2015 with a pilot program in Delaware and marked the first time that U.S. patients had access to the world's only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and neuropathy to name a few.
"After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities," says Robert Fireman, CEO of MariMed Inc. "Tikun Olam's empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun's products to tens of thousands of new patients nationwide."
MariMed will introduce Tikun's exclusive strains and products in state-of-the-art, regulatory compliant and fully operational cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be available in flower, vape cartridges, topicals, tinctures and edibles utilizing at least six Tikun™ branded strains, including its world-renowned Avidekel™ high-CBD strain. In addition to Delaware, Tikun™ products have launched in Nevada (March 2017) and are expected to launch Washington (November 2017).
"Tikun Olam is delighted to expand our relationship with MariMed," says Tikun CEO Bernard Sucher. "MariMed utilizes the "best practices" and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before."
About Tikun Olam
Tikun Olam ("repair the world" in Hebrew) is the world's leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Operating as a commercial venture for over 10 years, Tikun Olam's products have been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy.
Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, "high-less" strain Avidekel™, its popular high-THC strain Alaska™, and its "one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S. operations, established in 2015 as T.O. Global LLC, is a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada (TSX: LEAF), Australia, Germany and South Africa, all in support of its global mission to educate the traditional medical community and its patients on the applications of cannabis as a scientifically proven wellness product.
https://www.prnewswire.com/news-releases/cann...21768.html
Deal Combines Tikun Products & Unparalleled Research with MariMed's Cultivation & Distribution Networks
NEWTON, Mass. and NEW YORK, Sept. 19, 2017 /PRNewswire/ -- Tikun Olam, the world pioneer in cannabis research, and MariMed Inc. (OTCQB:MRMD), a preeminent management company in the U.S. medical cannabis industry, announced an expansion of their licensing agreement for Tikun Olam products to be grown, manufactured and sold through MariMed's network of managed and affiliated licensed facilities throughout the United States.
This new agreement brings Tikun Olam's premium cannabis products, years of proprietary, peer-reviewed scientific research and unprecedented clinical data collection to four additional MMJ-legal U.S. states, its most expansive agreement to date. Tikun Olam and MariMed's relationship began in 2015 with a pilot program in Delaware and marked the first time that U.S. patients had access to the world's only cannabis strains proven to deliver symptomatic relief for specific conditions including cancer, PTSD, epilepsy, Crohn's Disease/Colitis, chronic pain and neuropathy to name a few.
"After the great success of our program in Delaware, MariMed is excited to bring Tikun™ to our expanding national network of legal cannabis production and dispensary facilities," says Robert Fireman, CEO of MariMed Inc. "Tikun Olam's empirical data on clinical effectiveness is unsurpassed, and we look forward to educating healthcare professionals and offering Tikun's products to tens of thousands of new patients nationwide."
MariMed will introduce Tikun's exclusive strains and products in state-of-the-art, regulatory compliant and fully operational cultivation and medical marijuana dispensaries in Rhode Island, Maryland, Massachusetts and Illinois in 2018. Tikun products will be available in flower, vape cartridges, topicals, tinctures and edibles utilizing at least six Tikun™ branded strains, including its world-renowned Avidekel™ high-CBD strain. In addition to Delaware, Tikun™ products have launched in Nevada (March 2017) and are expected to launch Washington (November 2017).
"Tikun Olam is delighted to expand our relationship with MariMed," says Tikun CEO Bernard Sucher. "MariMed utilizes the "best practices" and standards for cultivation and production and their qualified distribution channels allow us to bring our proven wellness products to more U.S. patients than ever before."
About Tikun Olam
Tikun Olam ("repair the world" in Hebrew) is the world's leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. Operating as a commercial venture for over 10 years, Tikun Olam's products have been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy.
Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, "high-less" strain Avidekel™, its popular high-THC strain Alaska™, and its "one-to-one" CBD/THC strain Midnight™. Tikun Olam's U.S. operations, established in 2015 as T.O. Global LLC, is a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada (TSX: LEAF), Australia, Germany and South Africa, all in support of its global mission to educate the traditional medical community and its patients on the applications of cannabis as a scientifically proven wellness product.
https://www.prnewswire.com/news-releases/cann...21768.html
1
